Cyclic dinucleotide
The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
1. A compound having Formula (X):
R and R 2 are each independently a hydroxy group or a halogen atom;
B 1 consists of:
R 18 is hydrogen or C 1-6 alkyl;
R 19 is a halogen atom;
B 2 is:
and
Q 2 and Q 4 are each independently an oxygen atom or a sulfur atom,
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 2 , wherein the pharmaceutically acceptable salt is the triethylamine salt.
10. The compound of claim 2 , wherein the pharmaceutically acceptable salt is the sodium salt.
11. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
12. A method of treating a patient comprising administering to the patient a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the patient has cancer, wherein the activation of STING (stimulator of interferon genes) by said compound suppresses cancer cell growth in said cancer.
13. The compound of claim 1 , wherein R 19 is fluoro, or the compound is a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 , wherein R 1 is a hydroxy group or a fluoro atom, or the compound is a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 , wherein R 2 is a hydroxyl group or a fluoro atom, or the compound is a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 , wherein Q 4 is a sulfur atom, or the compound is a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 , wherein Q 2 is an oxygen atom, or the compound is a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 , wherein Q 2 is a sulfur atom, or the compound is a pharmaceutically acceptable salt thereof.
19. The compound of claim 1 , wherein the compound has the formula (XII):
or a pharmaceutically acceptable salt thereof.
20. The compound of claim 1 , wherein R 18 is hydrogen or methyl, or the compound is a pharmaceutically acceptable salt thereof.